SCHEMBL2804539

SCHEMBL2804539

[CH2]C[Si](C)(C)CCCCC

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 1/20 0.32
SLC22A1 O15245 2/20 0.30
SLC22A2 O15244 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803067 0.97 TSHR (0.42) TSHRTHRBLMNASLC22A1
SCHEMBL2806432 0.97 TSHR (0.42) TSHRTHRBLMNASLC22A1
SCHEMBL2805275 0.97 TSHR (0.42) TSHRTHRBLMNASLC22A1
SCHEMBL2589314 0.97 TSHR (0.42) TSHRTHRBLMNASLC22A1
SCHEMBL2802272 0.97 TSHR (0.42) TSHRTHRBLMNASLC22A1
SCHEMBL2804545 0.92
SCHEMBL2791955 0.82 TSHR (0.47) TSHRTHRBLMNASLC22A1SLC22A2
SCHEMBL8388564 0.79 TSHR (0.53) TSHRTHRBLMNASLC22A1
SCHEMBL2803996 0.79
SCHEMBL10356295 0.79 TSHR (0.53) TSHRTHRBLMNASLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785574-B2 Bridged metallocene compound, olefin polymerization catalyst containing the same, and ethylene polymer obtained with the catalyst MITSUI CHEMICALS, INC. (JP) 2014-07-22 US disclosed
US-20140114031-A1 BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST PRIME POLYMER CO., LTD. (JP) 2014-04-24 US disclosed
EP-2218725-B1 BRIDGED METALLOCENE OLEFIN POLYMERIZATION CATALYST AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST MITSUI CHEMICALS INC (JP) 2013-10-23 EP disclosed
US-20100292421-A1 BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST MITSUI CHEMICALS, INC. 2010-11-18 US disclosed
EP-2218725-A1 BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST Mitsui Chemicals, Inc. (JP) 2010-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292421-A1 BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST CAD, ENDOD1, CCT7 TSHR 4068/4885THRB 2758/4885LMNA 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.